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Developments in the Role of Endothelin-1 in Atherosclerosis: 
A Potential Therapeutic Target?
Greg Sutton, Dan Pugh, and Neeraj Dhaun
Atherosclerosis is a progressive inflammatory disease of the 
arterial intima defined by fatty plaques within the vessel 
wall.1 Plaques are characterized by the subendothelial 
build-up of low-density lipoprotein (LDL) leading to local 
inflammation and the accumulation of macrophage-derived 
foam cells. The development and subsequent rupture of 
atherosclerotic plaque leads to potentially catastrophic vas-
cular events such as myocardial infarction and stroke. Thus, 
prevention of this largely asymptomatic condition is vital. 
Our understanding of the pathogenesis of atherosclerosis 
has progressed significantly over the last 3 decades, broad-
ening the scope of preclinical studies and producing several 
exciting potential therapeutic targets. The role of the innate 
immune system and how it might interact with other key 
factors involved in atherogenesis have been the subject of 
much recent interest.2,3
Endothelin-1 (ET-1) may represent a novel therapeutic 
target for the treatment and prevention of atherosclerosis par-
ticularly through its interactions with macrophages.4 ET-1 is 
the most potent endogenous vasoconstrictor produced pri-
marily by the vascular endothelium. It has been implicated 
in endothelial dysfunction, inflammation, and vascular 
remodeling.5,6 It acts through 2 G protein-coupled receptors, 
the endothelin A (ETA) receptor and the endothelin B (ETB) 
receptor. Vascular smooth muscle cell ETA receptors mediate 
vasoconstriction whereas ETB receptors, mostly located on 
endothelial cells, mediate vasodilation. It is the actions of 
ET-1 through the ETA receptor that are considered most 
important in cardiovascular diseases, such as hypertension, 
chronic kidney disease, and atherosclerosis.6
Circulating ET-1 is increased in patients with atheroscle-
rosis.7 In 1995, Kowala et al. demonstrated that ETA receptor 
antagonism reduced fatty streak development in hyperlipi-
demic hamsters.8 These studies and others proposed the ra-
tionale that ET-1 may have a role in the early inflammatory 
phase of atherogenesis and that this may be amenable to 
treatment. Despite these findings, few clinical trials have 
attempted to address this. One study randomized 72 patients 
with non-obstructive coronary artery disease to receive ei-
ther the selective ETA receptor antagonist, atrasentan, or 
placebo for 6 months.9 The authors observed no significant 
difference in the progression of angiographic coronary ath-
eroma, perhaps unsurprising given the relatively short time 
period of the study. Nevertheless, there was a significant re-
duction in blood pressure in the treatment group and work 
from the same group later demonstrated that 6 months of 
atrasentan improved coronary endothelial function in a 
similar group of patients. Thus, one might anticipate less 
atherosclerosis progression if these effects are maintained 
longer term.
In this issue of the American Journal of Hypertension, 
Zhang et  al. explore the interplay between ET-1, endothe-
lial cells, and macrophages within the context of athero-
sclerosis.10 They initially make 2 observations. First, that 
apolipoprotein-E knockout (ApoE–/–) mice fed a high-fat 
diet have an increase in endothelial cell ET-1 protein expres-
sion within atherosclerotic plaques and second, that human 
umbilical vein endothelial cells (HUVECs) demonstrate an 
increase in ET-1 production on exposure to oxidized LDL 
(oxLDL). On the basis of these, the authors hypothesize that 
oxLDL stimulates endothelial ET-1 production, which then 
promotes progression of atheromatous plaque.
During a series of in vitro studies, using HUVECs 
adenovirally transfected to overexpress ET-1 (etHUVECs), 
Zhang et al. show that a combination of ET-1 overexpression 
and oxLDL promotes endothelial cell production of a range 
of adhesion molecules and chemokines. These effects are not 
seen with excess ET-1 alone and are greater than those seen 
with oxLDL. Monocyte chemoattractant protein-1 (MCP-1 
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assessed. These are key players in regulating the migration 
and infiltration of monocytes and macrophages.11 Thus, 
this finding provides a natural progression to performing a 
co-culture of (both mouse and human) macrophages with 
etHUVECs. Here, the authors find that, whereas ET-1 alone 
has no effect, a combination of ET-1 and oxLDL promotes 
macrophage migration. Interestingly, when macrophages 
are cultured with conditioned medium from etHUVECs 
treated with oxLDL, they develop a more inflammatory/
M1 phenotype and less of an anti-inflammatory/M2 one 
as demonstrated by upregulation of message encoding in-
terleukin-6 (IL6), tumor necrosis factor-α (TNFα), and in-
ducible nitric oxide synthase (iNOS) and downregulation of 
IL10 and mannose receptor. These findings are in line with 
previous work.12 Further experiments demonstrate that all 
of the inflammatory effects of ET-1 and oxLDL on endothe-
lial cells are dependent on an unblocked ETA receptor and 
functional protein kinase C (PKC) signaling (Figure 1). PKC 
has been shown to regulate ET-1 expression in diabetes13,14 
and its inhibition is being explored in a range of diseases.15
The authors then translate their in vitro findings in 
vivo using an ApoE–/– mouse with vascular endothelial 
overexpression of ET-1 (eET-1/ApoE–/–). They find that 
atherosclerotic plaque size is increased in these mice 
compared with relevant controls. In addition, plaques 
contained more cells expressing CD68, a protein highly 
expressed by cells of the monocyte lineage. Aortic tissue 
from these animals also showed heightened expression of 
pro-inflammatory but downregulation of anti-inflamma-
tory cytokines. The authors did not treat these mice with 
ET receptor blockers, which might have further dissected 
the role of ETA and/or ETB signaling in the effects seen. An 
upregulated ET system has been linked to inflammatory 
cell migration into vascular tissue and reactive oxygen 
species production and so some assessment of vascular 
function, e.g., using wire myography, might have been in-
formative.16 Other work has shown that chronically ele-
vated endothelial ET-1 leads to sustained blood pressure 
elevation and vascular and renal injury and that this is 
mediated via ETA receptors.17
Recent work has shown that ET-1 is a potent chemoat-
tractant for both mouse and human macrophages and that this 
is dependent on an unblocked macrophage ETB receptor with 
some contribution of ETA. This same study showed that ET-1 
alone or in combination with either classical or alternative ac-
tivation methods was unable to alter macrophage phenotype to 
any measurable extent.4 Zhang et al.’s finding that ET-1 alone 
does not influence macrophage phenotype is in keeping with 
these data. However, in their hands, ET-1 alone is insufficient 
to influence macrophage chemokinesis (unless in the presence 
of oxLDL), which is out of keeping with this earlier study. This 
may be due to the different experimental conditions used (e.g., 
endothelial cell line-derived ET-1 here vs exogenous ET-1).4
It is intriguing that ETA receptor antagonism prevented the 
inflammatory effects of combined ET-1 and oxLDL on endo-
thelial cells. Healthy vascular endothelial cells are considered 
to only express ETB receptors,18 although there have been 
reports of endothelial ETA expression in some disease states 
and specific cell lines.19 The authors used an ETA receptor an-
tagonist (BMS-182874) that is 1,000-fold selective for ETA 
over ETB so the effects seen are unlikely to be due to any 
functional ETB blockade. Also, it is interesting that at base-
line they found similar ETA and ETB expression in control 
HUVECs with etHUVECs expressing greater ETA than ETB. 
Thus, the findings from this study must be translated with 
some caution as they may be restricted to the cell lines used.
Both selective ETA and mixed ETA/B receptor antagonists 
(ERAs) are currently licensed and available in the clinic.6 
Thus, the current studies would have benefited from addi-
tional investigation of combined ETA/B receptor antagonism. 
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Therapeutic blockade of the ET system has been investigated 
for several cardiovascular disorders. These agents effectively 
reduce blood pressure in treatment-resistant hypertension 
and reduce proteinuria on top of standard care in patients 
with chronic kidney disease (CKD).4 Indeed, the recently 
published study of diabetic nephropathy with atrasentan 
(SONAR) demonstrated a significant reduction in CKD pro-
gression with atrasentan compared with placebo in patients 
with diabetic nephropathy.20 In addition, ERAs are first-line 
therapy for the management of pulmonary arterial hyperten-
sion, a rare but devastating condition. All these conditions are 
associated with accelerated atherosclerosis and so the authors 
should be commended for these data, which expand our 
knowledge with respect to the interaction between ET and in-
nate immune systems in the development of atherosclerosis.
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